---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-23-000046"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T00:40:58.766558+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix Q3 FY2023 revenue $18.5M, net loss $37.0M; Seagen collaboration yields $60M upfront

## Summary
- Revenue of $18.5M, up 71% YoY, driven by $8M in research milestones from Gilead and Sanofi.
- Net loss of $37.0M ($0.68 per share) narrowed from $45.7M ($0.90) YoY.
- Cash, equivalents and marketable securities $268.7M as of Aug 31, 2023; runway into Q2 2025.
- Strategic collaboration with Seagen: $60M upfront, potential $3.4B milestones, option for U.S. profit sharing on two DAC products.
- Expects initial clinical data from NX-5948, NX-2127, and NX-1607 Phase 1 trials in H2 2023.

## SEC filing metadata
- accession: 0001549595-23-000046
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000046/0001549595-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000046/nrix-20231012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-23-000046
- JSON: https://secwatch.observer/filing/0001549595-23-000046.json
- Plain text: https://secwatch.observer/filing/0001549595-23-000046.txt

## Key facts
- Earnings Releases
  Nurix Therapeutics, Inc. reported fiscal quarter ended August 31, 2023 results: revenue $18.5 million, net income $37.0 million, or ($0.68) per shar, EPS $(0.68).
  - Period: fiscal quarter ended August 31, 2023
  - Revenue: $18.5 million
  - Net income: $37.0 million, or ($0.68) per shar
  - EPS: $(0.68)
  - Result: reported results
  source text: Revenue for the three months ended August 31, 2023, was $18.5 million compared to $10.8 million for the three months ended August 31, 2022. The increase was primarily due to a higher percentage of completion of performance obligations and an increase in the value of milestones achieved in the current period. During the three months ended August 31, 2023, Nurix achieved research milestones under its collaborations with Gilead and Sanofi totaling $6.0 million and $2.0 million, respectively. Research and development expenses for the three months ended August 31, 2023, were $47.9 million compared to $47.8 million for the three months ended August 31, 2022. There was an increase in clinical costs as Nurix continued its clinical trial programs and ongoing patient enrollment, primarily offset by a decrease in research related costs and in contract manufacturing. There was also an increase in facility and other costs primarily driven by additional investments in information technology and leas
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000046/0001549595-23-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.